On October 19, 2023 NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, reported that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023 (Press release, NexImmune, OCT 19, 2023, View Source [SID1234636149]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that abstracts highlighting recent advances in our AIM injectable program demonstrating the ability to generate broad polyclonal T cell responses from memory and naive populations, as well as the synergistic benefit of a novel IO AIM ACT combination in the oncology setting, have been selected for presentation at SITC (Free SITC Whitepaper) 2023," said Kristi Jones, Chief Executive Officer of NexImmune. "These abstracts showcase the continued advancement of our platform and its therapeutic potential in cancer, autoimmune and infectious diseases."

Poster Presentation Details:

Title: Efficacy of injectable antigen presenting nanoparticles (AIM INJ), in solid tumor models
Abstract Number: 1139
Category: Poster Presentation
Authors: Haiyun Liu, Duong Nguyen, Durgadas Cherukaraveedu, Adam Parks, Bryan Hahn, Daniel Dembrow, Sojung Kim, Jack Ragheb, Aniket Wadajkar, Mathias Oelke
Date & Time: Friday, Nov. 3, 2023 9 a.m. – 7 p.m. Exhibit Hall A

Title: Enhancement of bispecific T Cell engagers (bispecific TCE) killing potency in AML with NexImmune Artificial Immune Modulation (AIM) Adoptive Cell Therapy (ACT) T cells
Abstract #: 395
Category: Poster Presentation
Authors: Ruipeng Wang, Mathias Oelke, Shweta Jain, Sojung Kim, Jack Ragheb, Adam Parks, Rui Wang, Charles Reed, Brian Alvarez, Jerome Zeldis, Daniel Bednarik
Date & Time: Friday, Nov. 3, 2023 9 a.m. – 7 p.m. Exhibit Hall A

Title: Artificial Immune Modulation (AIM) nanoparticles expand antigen specific CD8 T cells from both naïve and memory T cell populations
Abstract #: 396
Category: Poster Presentation
Authors: Ruipeng Wang, Lauren Suarez, Bryan Hahn, Alison Farrell, Sojung Kim and Mathias Oelke
Date & Time: Saturday, Nov. 4, 2023 9 a.m. – 8:30 p.m. Exhibit Hall A

All posters presented at the poster hall will be made available as virtual ePosters throughout the SITC (Free SITC Whitepaper) 38th Annual Meeting.